INTRODUCTION: Inflammatory @entity792 ( @entity309 , @entity1691 , @entity30 , @entity31 , @entity1569 , and @entity5144 ) have a considerable impact on @entity1 ' quality of life and healthcare budgets. Biosimilar infliximab (Remsima(  )) has been authorized by the European Medicines Agency for the management of inflammatory @entity792 based on a data package demonstrating efficacy, safety, and quality comparable to the reference infliximab product (Remicade(  )). This analysis aims to estimate the 1-year budget impact of the introduction of Remsima in five European countries. METHODS: A budget impact model for the introduction of Remsima in Germany, the UK, Italy, the Netherlands, and Belgium was developed over a 1-year time horizon. Infliximab-na  ve and switch @entity1 groups were considered. Only direct drug costs were included. The model used the drug-acquisition cost of Remicade. The list price of Remsima was not known at the time of the analysis, and was assumed to be 10-30% less than that of Remicade. Key variables were tested in the sensitivity analysis. RESULTS: The annual cost savings resulting from the introduction of Remsima were projected to range from < @entity7634 >2.89 million (Belgium, 10% discount) to < @entity7634 >33.80 million (Germany, 30% discount). If any such savings made were used to treat additional @entity1 with Remsima, 250 (Belgium, 10% discount) to 2602 (Germany, 30% discount) additional @entity1 could be treated. The cumulative cost savings across the five included countries and the six licensed disease areas were projected to range from < @entity7634 >25.79 million (10% discount) to < @entity7634 >77.37 million (30% discount). Sensitivity analyses showed the number of @entity1 treated with infliximab to be directly correlated with projected cost savings, with disease prevalence and @entity1 weight having a smaller impact, and incidence the least impact. CONCLUSION: The introduction of Remsima could lead to considerable drug cost-related savings across the six licensed disease areas in the five European countries. FUNDING: Mundipharma International Ltd.

The Budget Impact of Biosimilar Infliximab (Remsima(  )) for the Treatment of XXXX in Five European Countries.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"] @entity5144 :: ('MESH:D015535', 'Disease') :: ['psoriatic arthritis'] @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis'] @entity7634 :: ('9319', 'Species') :: ['euro']
@entity792 :: (MESH:D001327,Disease) :: ['Autoimmune Diseases']
